SOURCE: HeartStitch, Inc.

Heartstitch, Inc.

September 06, 2016 06:18 ET

HeartStitch® Presence in PFO Closure Hits New Milestone

Successful PFO Closures Completed in Multiple Countries Over One Week Using NobleStitch™ EL Suture Based System

FRANKFURT, GERMANY and MILAN, ITALY and ROME, ITALY and ALMATY, KAZAKHSTAN--(Marketwired - September 06, 2016) - HeartStitch® Inc, continues to increase its presence in Interventional Cardiology with continued successful cases worldwide. These recent cases proved that the NobleStitch™ EL system for PFO closure with its suture only technology is poised to be the device of choice for physicians around the world. The devices were successfully used in over 20 patients, at 5 Heart Centers, by 6 doctors, in 3 countries over the one-week period.

CEO and Inventor, Prof. Anthony Nobles stated, "As we bring this technology to more physicians and centers we are seeing the commitment growing in the PFO closure community. We find physicians embracing the opportunity to perform 'suture only' closures and rapidly converting from traditional 'umbrella' type metal implants. The NobleStitch™ EL system provides a high level of successful procedures the doctors demand, at the same time providing patients with treatment that only requires non-invasive sutures left behind in the body. Giving patients the highest quality of care both in-procedure and post-recovery along with providing Doctors the ability to have a device with ease-of-use with the highest of success rates is our goal at HeartStitch® on a daily basis."

During the week the five days of cases in Germany, Italy and Kazakhstan, Dr. Michael Mullen, Chief Medical Officer and Prof. Nobles, Chief Clinical Officer of HeartStitch® proctored several new physicians in the use of the NobleStitch™ EL expanding it's reach into several more new centers including Almaty, Kazakhstan, Milan and Rome, Italy and Frankfurt, Germany.

Prof. Achille Gaspardone, Director of Cardiology, Department of Medicine, Ospedale, S. Eugenio -- ASL RMC, Rome Italy was quoted in an interview just following the cases performed during this week. After performing the 13 successful cases in a row over 2 training sessions Prof. Gaspardone spoke about the NobleStitch™, "After 25 years we now have a revolutionary technology that will change our approach to therapy of PFO syndrome. With my initial experience with the NobleStitch™ it was clear that this is a revolution in our treatment of PFO and that this technique is going to be the first choice in the treatment of PFO. This is what I say to my patients, there is a new technique that has several positive factors compared to the traditional technique. If I were to be the patient my first choice is the direct suture (NobleStitch™). With this technique you don't leave in your heart a metallic disk which could be quite big. Something that disturbs me having done hundreds and hundreds (PFO closures) and in young people leaving a big prosthesis in the heart is disturbing. The advantage of the (NobleStitch™) system is you don't need anticoagulation treatment because you don't leave anything behind. At the end of the day when you do a procedure in a young patient like our patient (18 year old) you want to sleep well after. In this case (using NobleStitch™) you get to bed very happy."

About HeartStitch®

HeartStitch® Inc. was founded by Prof. Anthony Nobles with the intent of leveraging its technologies in the structural heart marketplace. HeartStitch® is focused on innovative suture-based systems for remotely providing suture repair of structural heart defects and other vascular structures.

The HeartStitch® TA and HeartStitch® MR are FDA cleared for vascular suturing in the United States. HeartStitch® manufactures and markets the NobleStitch™ EL under exclusive license from Nobles ​Medical technologies II, Inc. NobleStitch™ EL is FDA cleared for vascular suturing in the United States and CE Marked for cardio-vascular suturing and PFO closure in the European Union and the Republic of Kazakhstan, respectively.

HeartStitch® is a registered trademark of HeartStitch, Inc.

HeartStitch® TA for cardiac suturing and transapical access and closure

Covered by or for use under U.S. and international patents including one or more of U.S. Patent Nos. 5860990, 6117144, 6245079, 6551331, 6562052, 6733509, 7004952, 7090686, 7803167, 8197497, 8348962, 8469975, 8496676, and 8709020.

HeartStitch® MR for suturing an anatomical valve

Covered by or for use under U.S. and international patents including one or more of U.S. Patent Nos. 5860990, 6117144, 6245079, 6551331, 6562052, 6733509, 7004952, 7090686, 7803167, 8197497, 8348962, 8469975, 8496676, 8709020, and 8771296.

NobleStitch™ EL for PFO closure

Covered by or for use under U.S. and international patents including one or more of U.S. Patent Nos. 5860990, 6117144, 6245079, 6551331, 6562052, 6733509, 7004952, 7090686, 7803167, 8197497, 8197510, 8246636, 8348962, 8372089, 8469975, 8496676, 8709020, and 9131938.

For more on HeartStitch® visit http://www.heartstitch.com

The following files are available for download:

Contact Information